JP2022521233A - 桂皮酸を含む組成物及びその使用方法 - Google Patents

桂皮酸を含む組成物及びその使用方法 Download PDF

Info

Publication number
JP2022521233A
JP2022521233A JP2021548664A JP2021548664A JP2022521233A JP 2022521233 A JP2022521233 A JP 2022521233A JP 2021548664 A JP2021548664 A JP 2021548664A JP 2021548664 A JP2021548664 A JP 2021548664A JP 2022521233 A JP2022521233 A JP 2022521233A
Authority
JP
Japan
Prior art keywords
patient
cinnamic acid
pharmaceutical composition
composition
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021548664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521233A5 (enExample
Inventor
カリパーダ パハン，
Original Assignee
ラッシュ・ユニバーシティ・メディカル・センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラッシュ・ユニバーシティ・メディカル・センター filed Critical ラッシュ・ユニバーシティ・メディカル・センター
Publication of JP2022521233A publication Critical patent/JP2022521233A/ja
Publication of JP2022521233A5 publication Critical patent/JP2022521233A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021548664A 2019-02-25 2020-02-25 桂皮酸を含む組成物及びその使用方法 Withdrawn JP2022521233A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962810055P 2019-02-25 2019-02-25
US62/810,055 2019-02-25
PCT/US2020/019568 WO2020176432A1 (en) 2019-02-25 2020-02-25 Compositions including cinnamic acid and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022521233A true JP2022521233A (ja) 2022-04-06
JP2022521233A5 JP2022521233A5 (enExample) 2023-03-07

Family

ID=72238701

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548664A Withdrawn JP2022521233A (ja) 2019-02-25 2020-02-25 桂皮酸を含む組成物及びその使用方法

Country Status (9)

Country Link
US (1) US12478598B2 (enExample)
EP (1) EP3930704A4 (enExample)
JP (1) JP2022521233A (enExample)
KR (1) KR20210130772A (enExample)
CN (1) CN113473981A (enExample)
AU (1) AU2020229316A1 (enExample)
CA (1) CA3130761A1 (enExample)
EA (1) EA202192199A1 (enExample)
WO (1) WO2020176432A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202002639D0 (en) * 2020-02-25 2020-04-08 Ucl Business Ltd Therapy
WO2022093922A1 (en) * 2020-10-28 2022-05-05 Rush University Medical Center Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders
US20240350441A1 (en) * 2021-12-01 2024-10-24 Sava Healthcare Ltd Pharmaceutical formulation and a process for its preparation
US20250057793A1 (en) * 2021-12-16 2025-02-20 The United States Government As Represented By The Department Of Veterans Affairs Benzoic acid salts for treatment of nervous system injuries and disorders
WO2024201533A1 (en) * 2023-03-31 2024-10-03 Sava Healthcare Limited A parenteral composition of cinnamic acid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100479405B1 (ko) * 2002-05-24 2005-03-30 주식회사 싸이제닉 신남산 이합체, 그 제조방법 및 퇴행성 뇌질환 치료를위한 그의 용도
HUE053671T2 (hu) * 2014-01-17 2021-07-28 Univ Rush Medical Center Gliceril-tribenzoátot tartalmazó készítmény neurodegeneratív rendellenességben történõ alkalmazása
ES2799309T3 (es) * 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
EP4026545A1 (en) * 2014-11-19 2022-07-13 Rush University Medical Center Compositions and methods for treating lysosomal disorders
WO2017215593A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
EP3691630A4 (en) * 2017-10-06 2021-10-27 Rush University Medical Center USE OF A COMPOSITION CONTAINING BENZOATE TO TREAT GLYCINE ENCEPHALOPATHY
GB202002639D0 (en) 2020-02-25 2020-04-08 Ucl Business Ltd Therapy
WO2022093922A1 (en) * 2020-10-28 2022-05-05 Rush University Medical Center Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders
EP4281118A4 (en) * 2021-01-20 2025-01-01 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease

Also Published As

Publication number Publication date
CN113473981A (zh) 2021-10-01
EA202192199A1 (ru) 2021-12-17
EP3930704A4 (en) 2022-11-16
US20220133664A1 (en) 2022-05-05
KR20210130772A (ko) 2021-11-01
US12478598B2 (en) 2025-11-25
AU2020229316A1 (en) 2021-09-16
EP3930704A1 (en) 2022-01-05
WO2020176432A1 (en) 2020-09-03
CA3130761A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
US12478598B2 (en) Compositions including cinnamic acid and methods of use thereof
AU2022200277A1 (en) The use of a benzoate containing composition to treat glycine encephalopathy
US20210252173A1 (en) Stabilized polyunsaturated compounds and uses thereof
JP2019504024A (ja) 腎結石を治療する医薬製剤ならびにその製造方法および用法
US20230255910A1 (en) Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders
JP5566521B1 (ja) 膀胱・尿道協調不全改善剤
JP6454436B1 (ja) ペマフィブラートを含有する医薬
TWI920601B (zh) 降低血脂之組合物及其用途
CN116911513A (zh) 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用
EP4281118A1 (en) Improved treatment for globoid cell leukodsytrophy or krabbe disease
KR20040033002A (ko) 당뇨병성 신경 장해용 의약 조성물
JP2008502607A (ja) 痴呆の予防および治療におけるＬ−ｎ−ブチルフタリドの適用
US20260000703A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine
CN114984034A (zh) 一种寡糖类化合物的应用
EP4410286A1 (en) Pharmaceutical composition for preventing or treating alzheimer's disease
JPS59222412A (ja) 心臓疾患治療薬
HK40109264A (en) Pharmaceutical composition for preventing or treating alzheimer's disease
Buyse et al. TO 3 SNT-MC17/idebenone in Duchenne muscular dystrophy: long-term blinded controlled preclinical study in the mdx mouse followed by a 12 month double-blind randomized controlled trial in humans
JP2012136545A (ja) 痴呆の予防および治療におけるＬ−ｎ−ブチルフタリドの適用
WO2006057209A1 (ja) 血中遊離脂肪酸低下作用を有する医薬組成物
Meier et al. TO 2 Omigapil/SNT-317 prevents apoptosis and ameliorates the pathology of laminin-alpha2 deficient muscle dystrophy
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230227

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230425